Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.
Saved in:
| Title: | Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. |
|---|---|
| Authors: | Yamamoto J; School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan. yamamoto.j.0c42@m.isct.ac.jp., Asatsuma-Okumura T; Department of Cell Biology, Institute of Advanced Medical Sciences, Graduate School of Medicine, Nippon Medical School, Bunkyo, 113-8602, Japan., Ito T; Institute of Medical Science, Tokyo Medical University, Shinjuku, 160-8402, Japan., Iwai Y; Department of Cell Biology, Institute of Advanced Medical Sciences, Graduate School of Medicine, Nippon Medical School, Bunkyo, 113-8602, Japan., Handa H; Department of Molecular Pharmacology, Center for Future Medical Research, Institute of Medical Science, Tokyo Medical University, Shinjuku, 160-8402, Japan., Yamaguchi Y; School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan. |
| Source: | Scientific reports [Sci Rep] 2026 Feb 05; Vol. 16 (1). Date of Electronic Publication: 2026 Feb 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
